Power Morcellator Use Increases Cancer Risk, FDA Verifies

There is a 1-in-225 to 1-in-580 risk that women getting fibroid removal surgery through hysterectomies or myomectomies may have hidden uterine sarcomas, US FDA said Dec. 14, and verified that power morcellation use during the surgeries will result in higher rates of cancer recurrence.

US FDA said Dec. 14 a new review of medical studies shows a 1-in-225 to 1-in-580 risk that women who undergo surgery (hysterectomy or myomectomy) for presumed benign uterine fibroid growths may have hidden uterine cancers know as sarcomas, and that power morcellation during surgeries worsens outcomes.

The updated scientific data confirms earlier information that FDA had in 2014 on use of power morcellators for fibroid growth...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Gynecology and Urology

More from Device Area